-
Healthcare Resource Optimization of Different Formulations: Daratumumab SC Compared To Daratumumab IV for Treating Multiple Myeloma
Mar 10, 2025, 14:00 PM -
Analysis of Public Expenditure of Pharmaceutical Utilization of Female Infertility in Hungary in the Last Decade
Mar 10, 2025, 14:00 PM -
Payer Perspectives on ICER Evidence Reports: InsightsInto Utility for Coverage and Formulary Decision-Making
Mar 10, 2025, 14:00 PM -
Comparative Effectiveness of Powered Surgical Stapling in Patients Undergoing Minimally Invasive Thoracic Surgery
Mar 10, 2025, 14:00 PM -
Validation Evidence of Self-Reported Measures for Healthcare Resource Utilization in Adult Populations: A Systematic Review
Mar 10, 2025, 14:00 PM -
Cost Effectiveness Analysis of a Pharmacist-Led Clinical Decision Support System Powered by Machine Learning to Reduce Drug-Associated Acute Kidney Injury in the Adult Non-ICU Setting
Mar 10, 2025, 14:00 PM -
Real-World Treatment Patterns and Overall Survival (OS) of Patients With Metastatic Triple-Negative Breast Cancer (mTNBC) in Canada
Mar 10, 2025, 14:00 PM -
The Potential Clinical Impact of the Moderna Next-Generation COVID-19 mRNA-1283 Vaccine in United States (US) Adults
Mar 10, 2025, 14:00 PM -
Treatment Patterns in the Management of Multiple Myeloma in a Colombian HMO During 2015–2023: A Real-World Data Study
Mar 10, 2025, 14:00 PM -
Long-Term Cost-Effectiveness Analysis of Once-Weekly Insulin Icodec Versus Once-Daily Basal Insulin Analogues in Patients With Type 2 Diabetes in China
Mar 10, 2025, 14:00 PM -
An Economic Model to Estimate Costs of Adverse Events in Patients Treated With Lisocabtagene Maraleucel (liso-cel), Axicabtagene Ciloleucel (axi-cel), or Tisagenlecleucel (tisa-cel) for Relapsed/Refractory Follicular Lymphoma
Mar 10, 2025, 14:00 PM -
K2GC: Real-world Treatments and Outcomes Amongst Patients With Resectable Gastric (GC) and Gastroesophageal Junction Cancer (GEJC) in the United States (US)
Mar 10, 2025, 14:00 PM -
Surgical Versus Non-Surgical Treatment of Thoracolumbar Burst Fractures In Neurologically Intact Patients: A Cost-Utility Analysis
Mar 10, 2025, 14:00 PM -
Trends in Breast Cancer Drugs Approved by the US Food and Drug Administration, 1980-2024
Mar 10, 2025, 14:00 PM -
Healthcare Resource Utilization and Associated Costs in Patients With Transthyretin Cardiac Amyloidosis and Non-amyloid Heart Failure
Mar 10, 2025, 14:00 PM -
Empowering Healthcare Decision-Making: Leveraging Standardized Template for Enhanced Reliability and Efficiency in Budget Impact Analysis by Health Technology Assessment Agency
Mar 10, 2025, 14:00 PM -
Harnessing Digital Measures of Physical Function in Neurological Conditions: Findings From a Targeted Literature Review
Mar 10, 2025, 14:00 PM -
Comparison of Meaningful Score Difference Estimates From Longitudinal Item Response Theory and Anchor-Based Methods
Mar 10, 2025, 14:00 PM -
Assessing Stakeholder Perceptions of Product Portfolio Value Beyond Financial Benefit: Development of a Survey
Mar 10, 2025, 14:00 PM -
Updated 1-Year Fracture Incidence and Costs of Fragility Fractures in US Post-Fracture Patients Based on Commercial Claims Databases
Mar 10, 2025, 14:00 PM
